Skip to main content
. 2022 Jan 19;8(3):eabj5908. doi: 10.1126/sciadv.abj5908

Fig. 7. Antiviral drug discovery in liver-derived organoids harboring HEV.

Fig. 7.

(A) Screening a library of 94 antiviral agents in GT3 p6Luc organoids (ICOs). (B) HEV GT1 luciferase activity in organoids harboring GT1Luc replicon (FLO3, n = 5). (C) The inhibitory effect of homoharringtonine (HHT) and ribavirin in p6 Huh7 cells (n = 4 to 6). (D) IC50 and CC50 of homoharringtonine in p6Luc Huh7 cells (n = 5 to 6). (E) The inhibitory effect of homoharringtonine in p6Luc organoids (FLO1, n = 5). (F) The inhibitory effect of homoharringtonine in GT1Luc organoids (FLO1, n = 4 to 5). (G) The inhibitory effect of homoharingtonine and ribavirin in p6 organoids (FLO1, n = 4 to 5). (H) Schematic representation of drug combination treatment on organoids harboring p6Luc model. (I) The antiviral effects of homoharringtonine in combination with IFNα (FLO1, n = 4). (J) The antiviral effects of homoharringtonine in combination with ribavirin (FLO1, n = 4). (K) Synergy distribution of pairwise combination of IFNα and homoharringtonine (n = 4). (L) Synergy distribution of pairwise combination of ribavirin and homoharringtonine (n = 4). ZIP, zero interaction potency. Data are presented as means ± SD, *P < 0.05 and **P < 0.01.